The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part of a ...

Moderna was once a darling of the first Trump administration, which went to great lengths to help the company develop its Covid-19 vaccine that protected millions of people from the virus. Now the ...

Moderna’s seasonal influenza vaccine met its main goal in a large Phase 3 trial, reducing the risk of influenza-like illness in people 50 years and older by 27% compared with those given a marketed ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The new low-dose vaccine is one-fifth the size of ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...